BP CEO Refuses to Disclose When Share Buybacks Will Resume

U.S. Treasury yields have risen, with the 10-year Treasury yield increasing by 2.34 basis points to 5.3%, and the 30-year Treasury yield rising by 2.64 basis points to 5.656%.

S&P Global Ratings has downgraded Nike (NKE.US) credit rating to "A" with a negative outlook.

S&P Global Ratings: Nike (NKE.US) is undergoing a prolonged business transformation, and its cash flow is expected to decline significantly.

October 5th - ** Bristol-Myers Squibb (BMY.N) shares fell 1.9% to $60 in pre-market trading ** ** Leerink Partners downgraded the pharmaceutical company's stock rating from “Outperform” to “Market Perform” and lowered its target price from $73 to $59 ** ** As of the previous trading session's close, BMY had risen 13.4% year to date; the new target price implies about 3.5% downside ** ** The brokerage highlighted uncertainty around three key projects for BMY and noted approaching patent expirations ** ** Leerink warned that the experimental pulmonary drug admilparant may disappoint in terms of efficacy and safety, citing possible liver issues and low blood pressure; it cut 2032 sales forecast by 38% ** ** They questioned whether experimental anticoagulant milvexian can rival Bristol-Myers Squibb’s Eliquis in preventing strokes in patients with atrial fibrillation, and lowered 2032 sales forecast by 25% ** ** Even if the antipsychotic drug Cobenfy is approved for treating Alzheimer’s-related psychosis, demand may still be limited by the availability of lower-priced generic antipsychotics ** ** EPS forecast for 2032 was cut by 11% to $4.96 (For non-native speakers’ convenience, Reuters automatically translates articles into multiple languages; Reuters makes no guarantee of accuracy due to possible automated translation errors or lack of context, and accepts no liability for any damages caused by use of the machine translation. The machine-translated text is provided solely for reader convenience.)